US Bancorp
XGN icon

US Bancorp’s Exagen XGN Stock Holding History

US Bancorp’s Portfolio XGN Stock Details XGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-73
Closed -$1K – 4220
2021
Q4 		$1K Buy
+73
New +$855 ﹤0.01% 4043

Other funds holding XGN

CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return

US Bancorp's XGN Position: Q1 2022 in Review

US Bancorp sold out of Exagen (XGN) in Q1 2022, closing a stake of 73 shares — an estimated $1K sold.

US Bancorp first reported a position in XGN in Q4 2021 and held it in 1 quarter. The position peaked at $1K in Q4 2021. 53 funds tracked by Wall St. Rank hold XGN as of Q1 2022.

  • US Bancorp reported no remaining Exagen position as of Q1 2022 after selling out during the quarter.
  • US Bancorp sold 73 Exagen shares in Q1 2022, an estimated $1K.
  • US Bancorp first reported a position in Exagen in Q4 2021 and held it in 1 quarter.
  • US Bancorp's Exagen position peaked at $1K in Q4 2021.
  • 53 funds tracked by Wall St. Rank held Exagen as of Q1 2022.

Based on US Bancorp's 13F filing for Q1 2022, filed 11 May 2022.